Table 2.

Demographics and characteristics of patients included in the analysis. Data are given as n (%), mean ± s.d. or range. Patients with at least one PK sample were included in the analyses.

Characteristics	REAL 1 (%)	REAL 2 (%)	REAL JP (%)	Total somapacitan (%)	Total somatropin (%)
All, n	225 (68.2)	59 (17.9)	46 (13.9)	330 (100)	164 (100)
Population
hGH treatment-naïve	225 (100)	–	–	225 (68.2)	118 (72)
Previously hGH-treated	–	59 (100)	46 (100)	105 (31.8)	46 (28)
Gender
Female	119 (52.9)	26 (44.1)	22 (47.8)	167 (50.6)	83 (50.6)
Male	106 (47.1)	33 (55.9)	24 (52.2)	163 (49.4)	81 (49.4)
Racea
White/other	161 (71.6)	47 (79.7)	–	208 (63)	106 (64.6)
Asian Japanese	36 (16)	11 (18.6)	46 (100)	93 (28.2)	40 (24.4)
Asian non-Japanese	28 (12.4)	1 (1.7)	–	29 (8.8)	18 (11)
Ethnicity
Not Hispanic or Latino/unknown	210 (93.3)	59 (100)	46 (100)	315 (95.5)	156 (95.1)
Hispanic or Latino	15 (6.7)	–	–	15 (4.5)	8 (4.9)
Age group
18–64 years	196 (87.1)	48 (81.4)	34 (73.9)	278 (84.2)	136 (82.9)
From 65 years	29 (12.9)	11 (18.6)	12 (26.1)	52 (15.8)	28 (17.1)
Body weight (kg)
Mean ± s.d.	74.2 ± 21.7	82.3 ± 17.9	69.4 ± 22.7	75 ± 21.5	76.1 ± 21.9
Range	36–140.9	46.8–121.8	34.5–150.5	34.5–150.5	22.5–151.2
Age (years)
Mean ± S.D.	44.6 ± 14.8	48 ± 16.4	54.1 ± 12.1	46.5 ± 15.1	47.3 ± 15.4
Range	23–75	19–77	20.2–75.2	19–77	20–77
Start dose group
Patients > 60 years	38 (16.9)	16 (27.1)	16 (34.8)	70 (21.2)	42 (25.6)
Patients ≤ 60 years	128 (56.9)	34 (57.6)	26 (56.5)	188 (57)	96 (58.5)
Females on oral oestrogen	59 (26.2)	9 (15.3)	4 (8.7)	72 (21.8)	26 (15.9)

^aRace groups with fewer than 20 patients were included in the White/other group.

hGH, human growth hormone.